US Capitol Capsule: Biopharma tackles legislative, regulatory, market hurdles at BIO 2012
This article was originally published in Scrip
Executive Summary
While Washington was immersed in predicting the US Supreme Court's verdict on health care reform – with some soothsayers inevitably off beam – biopharmaceutical leaders from 65 countries last week were engaged 450 miles (724.2 kilometers) to the north in Boston in the largest networking discussion aimed at finding legislative, regulatory, scientific and market solutions for ensuring the viability of their companies and the industry at large.